🇺🇸 FDA
Pipeline program

SMT C1100

SMT C11003

Phase 1 small_molecule completed

Quick answer

SMT C1100 for Muscular Dystrophy, Duchenne is a Phase 1 program (small_molecule) at Summit Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Summit Therapeutics
Indication
Muscular Dystrophy, Duchenne
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials